Skip to main content
SpringerLink
Log in

Pulmonary Hypertension: Transition Challenges in the Current Therapeutic Era

  • Chapter
  • First Online:
Transitioning Care from Pediatric to Adult Pulmonology

Part of the book series: Respiratory Medicine ((RM))

Abstract

The management of pulmonary hypertension has evolved significantly over the past 30 years. The introduction of targeted pulmonary arterial hypertension pharmacotherapies revolutionized care for a once untreatable disease. With improved outcomes, an increasing number of pediatric patients are surviving into adulthood. However, patients face a significant morbidity burden, due to both the disease and the complex therapies used to treat it. This chapter reviews the epidemiology and pathophysiology of pulmonary hypertension, the impact the disease has on quality of life, and the aspects of care that are important to address during the transition process. Improved outcomes are seen when patients are well-educated about their disease, actively participate in their care, and are appropriately supported throughout their disease course.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lammers AE, Apitz C, Zartner P, Hager A, Dubowy KO, Hansmann G. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102 Suppl 2:ii1–13.

    PubMed  Google Scholar 

  2. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888–94.

    CAS  PubMed  Google Scholar 

  3. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1–13.

    Google Scholar 

  4. Assad TR, Maron BA, Robbins IM, Xu M, Huang S, Harrell FE, et al. Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol. 2017;2(12):1361–8.

    PubMed  PubMed Central  Google Scholar 

  5. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

    Google Scholar 

  6. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240–8.

    PubMed  PubMed Central  Google Scholar 

  7. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.

    CAS  PubMed  Google Scholar 

  8. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–99.

    PubMed  Google Scholar 

  9. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ. 2011;1(2):286–98.

    PubMed  PubMed Central  Google Scholar 

  10. Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696–703.

    CAS  PubMed  Google Scholar 

  11. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117–26.

    PubMed  Google Scholar 

  12. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916.

    PubMed  PubMed Central  Google Scholar 

  13. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.

    PubMed  Google Scholar 

  14. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl):20S–9S.

    PubMed  Google Scholar 

  15. Wijeratne DT, Lajkosz K, Brogly SB, Lougheed MD, Jiang L, Housin A, et al. Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018;11:e003973.

    PubMed  PubMed Central  Google Scholar 

  16. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755–64.

    PubMed  Google Scholar 

  17. Ivy D. Pulmonary hypertension in children. Cardiol Clin. 2016;34(3):451–72.

    PubMed  PubMed Central  Google Scholar 

  18. Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. J Clin Med. 2017;6(1):4.

    PubMed Central  Google Scholar 

  19. del Cerro Marin MJ, Sabate Rotes A, Rodriguez Ogando A, Mendoza Soto A, Quero Jimenez M, Gavilan Camacho JL, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med. 2014;190(12):1421–9.

    PubMed  Google Scholar 

  20. Hansmann G. Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol. 2017;69(20):2551–69.

    PubMed  Google Scholar 

  21. McGoon MD, Humbert M. Pulmonary arterial hypertension: epidemiology and registries. Advances in Pulmonary Hypertension. 2014;13:21–6.

    Google Scholar 

  22. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8–18.

    CAS  PubMed  Google Scholar 

  23. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012;125(1):113–22.

    PubMed  Google Scholar 

  24. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148(4):1043–54.

    PubMed  Google Scholar 

  25. Takatsuki S, Ivy DD. Current challenges in pediatric pulmonary hypertension. Semin Respir Crit Care Med. 2013;34(5):627–44.

    PubMed  PubMed Central  Google Scholar 

  26. Mathai SC. A rare opportunity in a rare disease. Adv Pulm Hypertens. 2018;16:175–8.

    Google Scholar 

  27. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21(Suppl K):K9–K20.

    PubMed  PubMed Central  Google Scholar 

  28. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143–55.

    PubMed  Google Scholar 

  29. Genetic Information Nondiscrimination Act of 2008, Pub L. No. 110-233, 122, Stat. 881.

    Google Scholar 

  30. Rosenzweig EB, Barst RJ. Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery. Prog Cardiovasc Dis. 2012;55(2):128–33.

    PubMed  Google Scholar 

  31. Gurvitz M, Valente AM, Broberg C, Cook S, Stout K, Kay J, et al. Prevalence and predictors of gaps in care among adult congenital heart disease patients: HEART-ACHD (the health, education, and access research trial). J Am Coll Cardiol. 2013;61:2180–4.

    PubMed  PubMed Central  Google Scholar 

  32. Zaidi AN, Daniels CJ. The Adolescent and Adult with Cogenital Heart Disease. In: Allen HD, Shaddy RE, Penny DJ, Cetta F, Feltes TF, editors. Moss and Adams’ heart disease ininfants, children, and adolescents: including the fetus and young adult. 9th ed. Philadelphia: Wolters Kulwer; 2016. p. 1559–99.

    Google Scholar 

  33. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112–8.

    CAS  PubMed  Google Scholar 

  34. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127(7):820–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005;129(4):449–64.

    CAS  PubMed  Google Scholar 

  37. Fonseca G, Souza R. Pulmonary hypertension in sickle cell disease. Curr Opin Pulm Med. 2015;21(5):432–7.

    CAS  PubMed  Google Scholar 

  38. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727–40.

    PubMed  PubMed Central  Google Scholar 

  39. Liem RI, Lanzkron S, Coates TD, DeCastro L, Desai AA, Ataga KI, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019;3(23):3867–97.

    PubMed  PubMed Central  Google Scholar 

  40. Hayes MM, Vedamurthy A, George G, Dweik R, Klings ES, Machado RF, et al. Pulmonary hypertension in sickle cell disease. Ann Am Thorac Soc. 2014;11(9):1488–9.

    PubMed  PubMed Central  Google Scholar 

  41. Centers for Disease Control and Prevention. HIV surveillance report, 2018 (Preliminary); vol. 30. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2019. Accessed 2 Apr 2020. 2018;30.

  42. UNAIDS. Global HIV & AIDS statistics - 2019 fact sheet. https://www.unaids.org/en/resources/fact-sheet. Published December 2019. Accessed 2 Apr 2020.

  43. Basyal B, Jarrett H, Barnett CF. Pulmonary hypertension in HIV. Can J Cardiol. 2019;35(3):288–98.

    PubMed  Google Scholar 

  44. Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res Ther. 2015;12:36.

    PubMed  PubMed Central  Google Scholar 

  45. Correale M, Palmiotti GA, Lo Storto MM, Montrone D, Foschino Barbaro MP, Di Biase M, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45(5):515–28.

    PubMed  Google Scholar 

  46. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, Poindexter BB, Finer NN, Ehrenkranz RA, Duara S, Sánchez PJ, O’Shea TM, Goldberg RN, Van Meurs KP, Faix RG, Phelps DL, Frantz ID 3rd, Watterberg KL, Saha S, Das A, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Bronchopulmonary dysplasia: definition, pathogenesis, and clinical features. Pediatrics. 2010;126:443–56.

    PubMed  PubMed Central  Google Scholar 

  47. Awerbach JD, Mallory GB Jr, Kim S, Cabrera AG. Hospital readmissions in children with pulmonary hypertension: a multi-institutional analysis. J Pediatr. 2018;195:95–101 e4.

    PubMed  Google Scholar 

  48. Varghese N, Rios D. Pulmonary hypertension associated with bronchopulmonary dysplasia: a review. Pediatr Allergy Immunol Pulmonol. 2019;32(4):140–8.

    PubMed  PubMed Central  Google Scholar 

  49. Altit G, Dancea A, Renaud C, Perreault T, Lands LC, Sant’Anna G. Pathophysiology, screening and diagnosis of pulmonary hypertension in infants with bronchopulmonary dysplasia - a review of the literature. Paediatr Respir Rev. 2017;23:16–26.

    PubMed  Google Scholar 

  50. Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med. 2010;182(2):237–45.

    PubMed  PubMed Central  Google Scholar 

  51. Caskey S, Gough A, Rowan S, Gillespie S, Clarke J, Riley M, et al. Structural and functional lung impairment in adult survivors of bronchopulmonary dysplasia. Ann Am Thorac Soc. 2016;13(8):1262–70.

    PubMed  Google Scholar 

  52. Gough A, Linden M, Spence D, Patterson CC, Halliday HL, McGarvey LP. Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. Eur Respir J. 2014;43(3):808–16.

    PubMed  Google Scholar 

  53. Blum R. Introduction. Improving transition for adolescents with special health care needs from pediatric to adult-centered health care. Pediatrics. 2002;110:1301–3.

    PubMed  Google Scholar 

  54. Blum RW, Garell D, Hodgman CH, Jorissen TW, Okinow NA, Orr DP, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 1993;14:570–6.

    CAS  PubMed  Google Scholar 

  55. White P, Cooley W, Transitions Clinical Report Authoring Group, American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians. Supporting the health care transition from adolescence to aduthood in the medical home. Pediatrics. 2018;142:e20182587.

    PubMed  Google Scholar 

  56. Kieckhefer G, Trahms C. Supporting development of children with chronic conditions: from compliance toward shared management. Pediatr Nurs. 2000;26:354–63.

    CAS  PubMed  Google Scholar 

  57. Actelion Pharmaceuticals Ltd. A holistic approach to patient care in pulmonary arterial hypertension. 2016. Date last accessed: March 2020. Date last updated: January 2016.

    Google Scholar 

  58. Graarup J, Ferrari P, Howard LS. Patient engagement and self-management in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):399–407.

    PubMed  Google Scholar 

  59. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J. 2019;53(1):1801919. https://doi.org/10.1183/13993003.01919-2018.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Saidi A, Kovacs AH. Developing a transition program from pediatric- to adult-focused cardiology care: practical considerations. Congenit Heart Dis. 2009;4:204–15.

    PubMed  Google Scholar 

  61. Knauth Meadows A, Bosco V, Tong E, Fernandes S, Saidi A. Transition and transfer from pediatric to adult care of young adults with complex congenital heart disease. Curr Cardiol Rep. 2009;11:291–307.

    PubMed  Google Scholar 

  62. Sable C, Foster E, Uzark K, Bjornsen K, Canobbio MM, Connolly HM, et al. Best practices in managing transition to adulthood for adolescents with congenital heart disease: the transition process and medical and psychosocial issues: a scientific statement from the American Heart Association. Circulation. 2011;123:1454–85.

    PubMed  Google Scholar 

  63. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative; 2014.

    Google Scholar 

  64. Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev. 2013;22(130):535–42.

    PubMed  Google Scholar 

  65. Actelion Pharmaceuticals. Supporting young adult living with pulmonary arterial hypertension (PAH) in the best practice management of their disease; 2017.

    Google Scholar 

  66. Chakinala M, McGoon M. Pulmonary hypertension care centers. Advances in Pulmonary Hypertension. 2014;12:175–8.

    Google Scholar 

  67. Talwar A, Garcia JGN, Tsai H, Moreno M, Lahm T, Zamanian RT, et al. Health disparities in patients with pulmonary arterial hypertension: a blueprint for action. An official American Thoracic Society statement. Am J Respir Crit Care Med. 2017;196(8):e32–47.

    PubMed  PubMed Central  Google Scholar 

  68. Oudiz RJ. Evolution in PH care: 3 decades of milestones. Advances in Pulmonary Hypertension. 2018;16:165–9.

    Google Scholar 

  69. Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant. 2012;31(4):364–72.

    PubMed  Google Scholar 

  70. Deano RC, Glassner-Kolmin C, Rubenfire M, Frost A, Visovatti S, McLaughlin VV, et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med. 2013;173(10):887–93.

    PubMed  Google Scholar 

  71. Wiener RS, Ouellette DR, Diamond E, Fan VS, Maurer JR, Mularski RA, et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest. 2014;145(6):1383–91.

    PubMed  PubMed Central  Google Scholar 

  72. Pulmonary Hypertension Association. PH Care Centers 2020 [cited Mar 30, 2020]. Available from: https://phassociation.org/phcarecenters/.

  73. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38(9):879–901.

    PubMed  Google Scholar 

  74. Coleman BA, Calderbank M. Transitioning the pediatric pulmonary hypertension patient (advances in pulmonary hypertension). Adv Pulm Hypertens. 2012;11:162–4.

    Google Scholar 

  75. Awerbach JD, Krasuski RA, Hill KD. Characteristics of pediatric pulmonary hypertension trials registered on ClinicalTrials.gov. Pulm Circ. 2017;7(2):348–360.

  76. Macitentan (Opsumit): for long-term treatment of pulmonary arterial hypertension [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. Table 1, Cost comparison table for drugs used for the treatment of pulmonary arterial hypertension. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349251/table/T30/.

  77. Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676.

    PubMed  PubMed Central  Google Scholar 

  78. Grady RM, Eghtesady P. Potts shunt and pediatric pulmonary hypertension: what we have learned. Ann Thorac Surg. 2016;101(4):1539–43.

    PubMed  Google Scholar 

  79. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016;25(142):418–30.

    PubMed  Google Scholar 

  80. LeVarge BL, Pomerantsev E, Channick RN. Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J. 2014;44(2):425–34.

    PubMed  PubMed Central  Google Scholar 

  81. Zhai Z, Zhou X, Zhang S, Xie W, Wan J, Kuang T, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine (Baltimore). 2017;96(39):e6783.

    Google Scholar 

  82. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med. 2019;19(1):67.

    PubMed  PubMed Central  Google Scholar 

  83. World Health Organization, World Bank. World report on disability; 2011.

    Google Scholar 

  84. Crossland DS, Jackson SP, Lyall R, Burn J, O’Sullivan JJ. Employment and advice regarding careers for adults with congenital heart disease. Cardiol Young. 2005;15:391–5.

    PubMed  Google Scholar 

  85. Americans with Disabilities Act of 1990, as amended, Pub. L. No. 110-336 Stat. 12101 (2009).

    Google Scholar 

  86. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2017;135:e50–87.

    PubMed  Google Scholar 

  87. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–241.

    PubMed  Google Scholar 

  88. Ambrisentan REMS. Ambrisentan REMS guide for female patients; 2019.

    Google Scholar 

  89. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):431–7.

    PubMed  Google Scholar 

  90. Veletri (epoprostenol). Dec 2012. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022260s005lbl.pdf. Last accessed: April 2020.

  91. Orenitram (Treprostinil). Jan 2017. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203496s006lbl.pdf. Last accessed: April 2020.

  92. UPTRAVI (selexipag). Dec 2015. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf. Date last accessed: April 2020.

  93. Simonneau G, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. https://doi.org/10.1183/13993003.01913-2018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Ezekian JE, Hill KD. Management of pulmonary arterial hypertension in the pediatric patient. Curr Cardiol Rep. 2019;21(12):162.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Phoenix Children’s Hospital, Department of Cardiology, Phoenix, AZ, USA

    Jordan D. Awerbach & Wayne J. Franklin

Authors
  1. Jordan D. Awerbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wayne J. Franklin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordan D. Awerbach .

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Critical Care,Occupational, and Sleep Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Cynthia D. Brown

  2. Department of Pulmonary, Critical Care, and Sleep Medicine, Wyoming Medical Center, Casper, WY, USA

    Erin Crowley

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Awerbach, J.D., Franklin, W.J. (2021). Pulmonary Hypertension: Transition Challenges in the Current Therapeutic Era. In: Brown, C.D., Crowley, E. (eds) Transitioning Care from Pediatric to Adult Pulmonology. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-68688-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-68688-8_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-68687-1

  • Online ISBN: 978-3-030-68688-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation